Targeting mast cells in gastric cancer with special reference to bone metastases 2015 advances in gastric cancer

Christian Leporini, Michele Ammendola, Ilaria Marech, Giuseppe Sammarco, Rosario Sacco, Cosmo Damiano Gadaleta, Caroline Oakley, Emilio Russo, Giovambattista De Sarro, Girolamo Ranieri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis. Both primary GC and its metastatic progression rely on angiogenesis. Several lines of evidence from GC patients strongly support the involvement of mast cells (MCs) positive to tryptase (MCPT) in primary gastric tumor angiogenesis. Recently, we analyzed infiltrating MCs and neovascularization in bone tissue metastases from primary GC patients, and observed a significant correlation between infiltrating MCPT and angiogenesis. Such a finding suggested the involvement of peritumoral MCPT by infiltrating surrounding tumor cells, and in bone metastasis angiogenesis from primary GC. Thus, an MCPT-stimulated angiogenic process could support the development of metastases in bone tissue. From this perspective, we aim to review the hypothetical involvement of tumorinfiltrating, peritumoral MCPT in angiogenesis-mediated GC cell growth in the bone microenvironment and in tumor-induced osteoclastic bone resorption. We also focus on the potential use of MCPT targeting agents, such as MCs tryptase inhibitors (gabexate mesylate, nafamostat mesylate) or c-KitR tyrosine kinase inhibitors (imatinib, masitinib), as possible new anti-angiogenic and anti-resorptive strategies for the treatment of GC patients affected by bone metastases.

Original languageEnglish
Pages (from-to)10493-10501
Number of pages9
JournalWorld Journal of Gastroenterology
Volume21
Issue number37
DOIs
Publication statusPublished - Oct 7 2015

Fingerprint

Tryptases
Mast Cells
Stomach Neoplasms
Neoplasm Metastasis
Bone and Bones
Gabexate
Tumor Microenvironment
Bone Development
Bone Resorption
Protein-Tyrosine Kinases
Neoplasms
Stomach

Keywords

  • Angiogenesis
  • Anti-angiogenic therapy
  • Bone metastases
  • C-kit receptor tyrosine kinase inhibitors
  • Gastric cancer
  • Osteoclastic bone resorption
  • Receptor activator of nuclear factor-κB
  • Tryptase inhibitors

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Targeting mast cells in gastric cancer with special reference to bone metastases 2015 advances in gastric cancer. / Leporini, Christian; Ammendola, Michele; Marech, Ilaria; Sammarco, Giuseppe; Sacco, Rosario; Gadaleta, Cosmo Damiano; Oakley, Caroline; Russo, Emilio; De Sarro, Giovambattista; Ranieri, Girolamo.

In: World Journal of Gastroenterology, Vol. 21, No. 37, 07.10.2015, p. 10493-10501.

Research output: Contribution to journalArticle

Leporini, Christian ; Ammendola, Michele ; Marech, Ilaria ; Sammarco, Giuseppe ; Sacco, Rosario ; Gadaleta, Cosmo Damiano ; Oakley, Caroline ; Russo, Emilio ; De Sarro, Giovambattista ; Ranieri, Girolamo. / Targeting mast cells in gastric cancer with special reference to bone metastases 2015 advances in gastric cancer. In: World Journal of Gastroenterology. 2015 ; Vol. 21, No. 37. pp. 10493-10501.
@article{dc55144a08604130a1d7514da6fe1b7b,
title = "Targeting mast cells in gastric cancer with special reference to bone metastases 2015 advances in gastric cancer",
abstract = "Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis. Both primary GC and its metastatic progression rely on angiogenesis. Several lines of evidence from GC patients strongly support the involvement of mast cells (MCs) positive to tryptase (MCPT) in primary gastric tumor angiogenesis. Recently, we analyzed infiltrating MCs and neovascularization in bone tissue metastases from primary GC patients, and observed a significant correlation between infiltrating MCPT and angiogenesis. Such a finding suggested the involvement of peritumoral MCPT by infiltrating surrounding tumor cells, and in bone metastasis angiogenesis from primary GC. Thus, an MCPT-stimulated angiogenic process could support the development of metastases in bone tissue. From this perspective, we aim to review the hypothetical involvement of tumorinfiltrating, peritumoral MCPT in angiogenesis-mediated GC cell growth in the bone microenvironment and in tumor-induced osteoclastic bone resorption. We also focus on the potential use of MCPT targeting agents, such as MCs tryptase inhibitors (gabexate mesylate, nafamostat mesylate) or c-KitR tyrosine kinase inhibitors (imatinib, masitinib), as possible new anti-angiogenic and anti-resorptive strategies for the treatment of GC patients affected by bone metastases.",
keywords = "Angiogenesis, Anti-angiogenic therapy, Bone metastases, C-kit receptor tyrosine kinase inhibitors, Gastric cancer, Osteoclastic bone resorption, Receptor activator of nuclear factor-κB, Tryptase inhibitors",
author = "Christian Leporini and Michele Ammendola and Ilaria Marech and Giuseppe Sammarco and Rosario Sacco and Gadaleta, {Cosmo Damiano} and Caroline Oakley and Emilio Russo and {De Sarro}, Giovambattista and Girolamo Ranieri",
year = "2015",
month = "10",
day = "7",
doi = "10.3748/wjg.v21.i37.10493",
language = "English",
volume = "21",
pages = "10493--10501",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "37",

}

TY - JOUR

T1 - Targeting mast cells in gastric cancer with special reference to bone metastases 2015 advances in gastric cancer

AU - Leporini, Christian

AU - Ammendola, Michele

AU - Marech, Ilaria

AU - Sammarco, Giuseppe

AU - Sacco, Rosario

AU - Gadaleta, Cosmo Damiano

AU - Oakley, Caroline

AU - Russo, Emilio

AU - De Sarro, Giovambattista

AU - Ranieri, Girolamo

PY - 2015/10/7

Y1 - 2015/10/7

N2 - Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis. Both primary GC and its metastatic progression rely on angiogenesis. Several lines of evidence from GC patients strongly support the involvement of mast cells (MCs) positive to tryptase (MCPT) in primary gastric tumor angiogenesis. Recently, we analyzed infiltrating MCs and neovascularization in bone tissue metastases from primary GC patients, and observed a significant correlation between infiltrating MCPT and angiogenesis. Such a finding suggested the involvement of peritumoral MCPT by infiltrating surrounding tumor cells, and in bone metastasis angiogenesis from primary GC. Thus, an MCPT-stimulated angiogenic process could support the development of metastases in bone tissue. From this perspective, we aim to review the hypothetical involvement of tumorinfiltrating, peritumoral MCPT in angiogenesis-mediated GC cell growth in the bone microenvironment and in tumor-induced osteoclastic bone resorption. We also focus on the potential use of MCPT targeting agents, such as MCs tryptase inhibitors (gabexate mesylate, nafamostat mesylate) or c-KitR tyrosine kinase inhibitors (imatinib, masitinib), as possible new anti-angiogenic and anti-resorptive strategies for the treatment of GC patients affected by bone metastases.

AB - Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis. Both primary GC and its metastatic progression rely on angiogenesis. Several lines of evidence from GC patients strongly support the involvement of mast cells (MCs) positive to tryptase (MCPT) in primary gastric tumor angiogenesis. Recently, we analyzed infiltrating MCs and neovascularization in bone tissue metastases from primary GC patients, and observed a significant correlation between infiltrating MCPT and angiogenesis. Such a finding suggested the involvement of peritumoral MCPT by infiltrating surrounding tumor cells, and in bone metastasis angiogenesis from primary GC. Thus, an MCPT-stimulated angiogenic process could support the development of metastases in bone tissue. From this perspective, we aim to review the hypothetical involvement of tumorinfiltrating, peritumoral MCPT in angiogenesis-mediated GC cell growth in the bone microenvironment and in tumor-induced osteoclastic bone resorption. We also focus on the potential use of MCPT targeting agents, such as MCs tryptase inhibitors (gabexate mesylate, nafamostat mesylate) or c-KitR tyrosine kinase inhibitors (imatinib, masitinib), as possible new anti-angiogenic and anti-resorptive strategies for the treatment of GC patients affected by bone metastases.

KW - Angiogenesis

KW - Anti-angiogenic therapy

KW - Bone metastases

KW - C-kit receptor tyrosine kinase inhibitors

KW - Gastric cancer

KW - Osteoclastic bone resorption

KW - Receptor activator of nuclear factor-κB

KW - Tryptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84942783603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942783603&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i37.10493

DO - 10.3748/wjg.v21.i37.10493

M3 - Article

VL - 21

SP - 10493

EP - 10501

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 37

ER -